HER2-low转移性子宫内膜癌对disitamab vedotin完全反应的病例报告与文献综述表2
一份关于HER2-low转移性子宫内膜癌患者使用disitamab vedotin后完全缓解的病例报告与文献综述表格。
基本信息
资源简介
HER2-low转移性子宫内膜癌对disitamab vedotin完全反应的病例报告与文献综述表2
【一句话概览】
本数据集是 figshare 公开的文本数据集，收录 1 个文件、合计 12.48 KB，主题涵盖 endometrial cancer、HER2-low、ADCS、RC48、recurrent metastasis，可用于医学自然语言处理（实体识别、信息抽取等），CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Table 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx》。配套论文《HER2 expression patterns in paired primary and metastatic endometrial cancer lesions》发表于 British Journal of Cancer（2017），DOI：10.1038/bjc.2017.422。源站首次发布：2024-09-16。
【数据内容】
源站原始描述：Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. The prognosis for patients diagnosed with early-stage EC remains favorable; however, for patients with recurrent or metastatic EC, the prognosis is poor and treatment options, until recently, are limited. Antibody drug conjugates (ADCs) represent innovative strategies in cancer treatment; however, there are less investigations regarding their efficacy in EC. This report describes an EC case with…
【数据结构与技术规格】
文件数 1 个，合计 12.48 KB。Table 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，12.48 KB。数据集 DOI：10.3389/fonc.2024.1367140.s002。
【主题与分类】
源站学科分类：Oncology and Carcinogenesis not elsewhere classified。主题标签：endometrial cancer、HER2-low、ADCS、RC48、recurrent metastasis、complete response。
【适用方向】
文本类数据可用于医学自然语言处理，如命名实体识别、信息抽取与文本分类。
【获取与许可】
源站页面：https://frontiersin.figshare.com/articles/dataset/Table_2_Complete_response_to_disitamab_vedotin_in_HER2-low_metastatic_endometrial_carcinoma_a_case_report_and_review_of_the_literature_docx/27022897
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Feng, Hu; Bi, Shasha; Sun, Shanshan; Yang, Hongbo; Zhou, Haoxing; Mao, Jingjing; et al. (2024). Table 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx. Frontiers. Dataset
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Table 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx
- DOI：10.3389/fonc.2024.1367140.s002
- 发布日期：2024-09-16
- 文件数：1 个
- 文件总体积：12.48 KB
- 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_2_Complete_response_to_disitamab_vedotin_in_HER2-low_metastatic_endometrial_carcinoma_a_case_report_and_review_of_the_literature_docx/27022897
命令行下载
curl -L -o "Table 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx" "https://ndownloader.figshare.com/files/49201024"
文件清单
Table 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx（12.48 KB）
文件总体积 12.48 KB（源站 API 实测）。
数据说明
Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. The prognosis for patients diagnosed with early-stage EC remains favorable; however, for patients with recurrent or metastatic EC, the prognosis is poor and treatment options, until recently, are limited. Antibody drug conjugates (ADCs) represent innovative strategies in cancer treatment; however, there are less investigations regarding their efficacy in EC. This report describes an EC case with low human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) expression score (IHC 2+) that experienced recurrent metastasis in the abdominal and peritoneal following post-surgical chemotherapy and radiotherapy. Subsequently, the commencement of HER2-targeted ADC, disitamab vedotin (RC48; 2.5 mg/kg), administered intravenously every two weeks, was initiated. The tumor lesions shrunk markedly after three cycles of treatment and disappeared by the completion of ten cycles of therapy. The patient is still in remission at present. The current findings imply the potential efficacy of HER2-targeted ADCs for patients with HER2-low metastatic EC.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.3389/fonc.2024.1367140.s002（source: https://frontiersin.figshare.com/articles/dataset/Table_2_Complete_response_to_disitamab_vedotin_in_HER2-low_metastatic_endometrial_carcinoma_a_case_report_and_review_of_the_literature_docx/27022897）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
